Preclinical
The results published in the NEJM state that pegcetacoplan met the study’s primary endpoint for efficacy, demonstrating an advantage over eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p<0.001). An impressive 85% of patients were transfusion free at 16 weeks, in contrast to only 15% of eculizumab-treated patients.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 2, 2021.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 2, 2021.
Elevian believes that this single protein, a key player in the circulatory system, could be a game-changer in regenerative medicine.
While the ATLAS platform has the potential to lead to an effective vaccine in itself, its greatest impact in the field of immunotherapy may be that it offers a new way of understanding how a tumor evades the therapy’s boundaries by identifying bad Inhibigens that lead to suppressive, or inhibitory, responses.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 26, 2021.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 19, 2021.
The novel immune checkpoint inhibitor Sanofi deemed worthy of such an investment is BND-22, a humanized IgG4 antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor, an inhibitory receptor expressed on both innate and adaptive immune cells.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 5, 2021.
PRESS RELEASES